Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus platinum-doublet chemotherapy as first-line treatment for advanced G3 gastroenteropancreatic or unknown-primary neuroendocrine neoplasms
2019-001546-18Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jun 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, carboplatin and etoposide in apudoma (NET) and islet cell tumor, sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Overall survival rate. Started Jun 2019; status: active.
02
Drugs
03
Conditions
apudoma (NET)islet cell tumor
Beyond the preview
Go deeper on 2019-001546-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001546-18.